152 - Challenges and Strategies in Peptide Drug Synthesis and Manufacturing (S11E2)

You know, we often hear about these exciting
new medical treatments. And it's easy to just
assume that once a discovery is made, getting
it to patients is simple. Right, like it's a
straight shot from the lab bench to the pharmacy
shelf. Exactly. But have you ever really stopped
to think about all the hidden stuff, the complexities,
especially with something like peptide therapeutics?
Absolutely. And that's really what we're digging
into today. We want to explore those. significant
hurdles involved in actually making these promising
peptide therapies. Not just discovering them,
but manufacturing them at scale. Yeah, at the
scale needed to actually help lots of people.
We'll be looking at, you know, how they're synthesized,
the molecules themselves, and also the really
critical need for strict quality standards. It's
called CGMP. TGMP, right? Good manufacturing
practice. Current good manufacturing practice,
yeah. And then there's the whole regulatory validation
side for these active ingredients, the APIs.
the actual drug part. Got it. And we've looked
through quite a bit of material for this, scientific
articles, pharma development guides, regulatory
stuff. We have. The idea is really to give you,
our listener, a clearer picture of these often
unseen challenges, bringing these innovations
from the lab to the patient. OK, so let's jump
right in, maybe start with the basics. What exactly
are peptide therapeutics? What makes them interesting?
So peptides. They're basically short chains of
amino acids think of them like Well smaller cousins
of proteins in our body. Okay smaller than proteins
Yeah, and what's cool about them is they can
sort of fit into this unique niche in medicine
You can design them to be super specific target
very particular things in the body exactly target
specific biological processes Which often means
they can be really potent but potentially with
fewer broad side effects compared to traditional
small molecule drugs. Interesting. But that complex
structure. That's also what makes making them
manufacturing them pretty challenging. Right.
So they hold a lot of promise, but that promise
comes with some difficulties in production. Where
do things start to get tricky typically? Well,
one of the first big roadblocks is just the synthesis,
actually building the peptide molecules. Making
the chain. Yeah. It sounds like maybe just linking
amino acids together, but doing that correctly
and on the kind of scale you need for medicine.
It's way more involved than making, say, a lot
of standard small molecule drugs. Why is it so
much more complicated? What's the specific challenge
there? Well, imagine you're building a very specific,
very long necklace with different colored beads
in a precise order. OK. For longer peptides,
making sure every single link is right and you
end up with the exact sequence that gets harder
and harder. Any mistake is a problem. A big problem.
Any mistakes in that process can lead to impurities.
Oh, impurities. Yeah, molecules that have the
wrong sequence or maybe they're missing bits
or they have extra chemical groups stuck on them.
And these impurities can really mess with the
drug's safety and how well it works. That makes
total sense. Like, misspelling a word in a long
sentence, it could change the whole meaning or
just be nonsense. Precisely. Now, the most common
way people make these peptides, synthesis -wise,
is something called solid phase peptide synthesis.
S -P -P -S. Okay. Yeah. Now, our sources don't
dive into all the nitty -gritty chemistry details,
but the basic idea is you build the peptide chain
step by step while it's attached to a solid support.
Like attached to little beads or something. Exactly.
Tiny beads in the reaction vessel. And that attachment
makes it easier to wash away all the leftover
chemicals and bi -products after each step. You
add an amino acid, wash, add the next, wash.
So you're kind of growing the peptide molecule
on these little anchors. That's a good way to
put it. And while SPPS is super common, taking
it from a small lab flask to producing kilograms,
maybe even tons, of a peptide, that's where the
real scaling challenges come in. Right. What
happens then? Well, for instance, making sure
each step is really efficient, like nearly 100
% complete, across a huge batch, that gets much
tougher. Consistency is harder. Much harder.
And the quality of the solid support itself,
those beads, can become an issue at large scale.
Plus, the sheer amount of chemicals you need,
that becomes a huge logistical and cost factor.
And are there other ways besides SPPS? Oh yeah,
there are other methods. like liquid phase synthesis
where everything's dissolved. But SQPS is often
favored because cleaning up the product, the
purification, can be relatively simpler, even
with its own scale of headaches. I feel like
I've also heard about microwaves being used sometimes.
Does that help with these scaling problems? That's
a good point. Microwave assistance. It is a technique
used in peptide synthesis. They can potentially
speed things up, the chemical reactions, maybe
improve the yields, but actually applying that
effectively at a really large industrial scale
that still has engineering hurdles. Getting even
micro reheating throughout a massive reactor
isn't trivial. So it's promising, maybe, but
not like a magic bullet for large -scale production
yet. Not universally, no. Bottom line, whichever
synthesis technique you use, getting that high
purity and a good yield when you're making huge
amounts, that remains a major challenge. And
you mentioned purity being critical because of
impurities affecting safety and efficacy. Exactly.
Any unwanted stuff in that final drug product
could, best case, make it less effective. Worst
case, cause unexpected side effects or even be
toxic. Which is obviously something you absolutely
have to avoid. Right. And that leads directly
into the next big challenge, actually scaling
up the entire manufacturing process, not just
the synthesis, while keeping that quality control
airtight. Taking it from the lab process to a
reliable factory process. Yeah, translating something
that works beautifully in a little glass flask
to something that works reliably, consistently,
day in, day out in a giant stainless steel vessel.
That's a massive undertaking. What kind of specific
problems pop up during that jump lab to factory?
Oh, several things. First, just getting your
raw materials. You need large volumes, consistently
high quality. Sourcing that reliably can be tough.
Supply chain issues. Big time. Then, the equipment
itself. Industrial reactors behave differently
than lab glassware. Heat transfer is different.
Mixing is different. So you often have to significantly
re -optimize the process. Adjusting all the parameters.
Reaction times, temperatures, how you purify
it. Everything might need tweaking and revalidation
when you're dealing with much bigger batches.
You need a process that's robust. Robust meaning?
Meaning it can handle slight variations in conditions
or materials without the final quality suffering.
It has to produce the exact same quality product
meeting specifications batch after batch after
batch. It's not just about making more. It's
making more perfectly every time. That's the
goal. It sounds like a really delicate balancing
act. It absolutely is. And this is where that
term C -G -M -P becomes so important. You mentioned
it earlier. What exactly is C -G -M -P and why
is it so central here? Right. C -G -M -P. Current
Good Manufacturing Practice. These are basically
the rules, the regulations, like in the U .S.
you have 21 CFR parts 210 and 211 that set the
minimum standards for making pharmaceuticals.
Minimum standards for everything involved? Pretty
much. They provide a framework to ensure the
drug's quality, safety, and effectiveness. It
covers everything from the building itself, the
equipment, how personnel are trained, the documentation,
all of it. So it's like a comprehensive rulebook
for safe and consistent drug manufacturing. That's
a good way to think about it. And for peptide
APIs, some CGMP aspects are especially critical.
Let's talk quality control, for example. OK,
testing things. Rigorous testing at every single
stage. You test the starting materials, you test
things during the synthesis, the intermediates,
and you test the final API. All to make sure
they meet preset. quality standards. Specifications.
Exactly, specifications. And there are international
guidelines, like ICH Q6A, that help define how
you set those specs. You need really sophisticated
tests, analytical methods that can precisely
identify the peptide and measure any tiny amounts
of impurities. Impurities, again, they seem to
be a constant theme here. They really are a primary
focus in peptide manufacturing. because the synthesis
itself can create all sorts of related but unwanted
molecules. Right, side products. Exactly. So
you need analytical methods that are super sensitive
and reliable, not just to detect impurities,
but ideally to figure out what they are, characterize
them, and make sure they're controlled below
safe limits. So you know it's there and ensure
it's not harmful. Precisely. This whole rigorous
approach to impurity control... It's fundamental
to making safe medicines, especially for complex
things like peptides. And I bet you need to write
everything down. Oh, absolutely. Meticulous records.
CGMP demands incredibly detailed and accurate
documentation. Every step of manufacturing, every
test result, any time something deviates even
slightly from the plan, it all has to be recorded.
Why so much paperwork? It creates a complete
audit trail. If there's ever a problem with a
batch later, you can trace its entire history.
And it's how you prove to regulators that you
followed all the rules. It's like the ultimate
lab notebook for the entire factory process.
Kind of, yeah. But legally binding. Okay. What
about the place where they're made? The building
and the machines? Also covered by CGMP, the design,
how they're maintained, making sure the equipment
is qualified, meaning it does what it's supposed
to do reliably. Okay. Facilities have to be set
up to prevent contamination. The air handling
systems, water purity, how things are cleaned
and sterilized, it's all tightly controlled.
And the people running the machines. Critically
important. CGMP requires that everyone involved,
from manufacturing operators to quality control
analysts, is properly trained and qualified for
their specific job. Makes sense. Minimizes human
error. Exactly. Trained people following validated
procedures consistently. That reduces the risk
of mistakes that could impact quality. You also
mentioned process validation earlier as part
of CGMP. What's that? Process validation. This
links into guidelines like ICH Q8 on pharmaceutical
development. It's essentially about proving,
with solid data, that your manufacturing process
consistently produces a product meeting, its
predetermined specifications, and quality attributes.
So it's not just testing the final stuff, but
proving the process works reliably. Yes. It's
about understanding your process deeply, gathering
data throughout development and manufacturing
to show it's reliable and under control. You
identify the critical factors that could affect
quality. Like temperature or mixing speed. Exactly.
And you show that even if those parameters vary
slightly within acceptable limits, the final
API quality isn't negatively impacted. You demonstrate
robustness. So you're basically proving to the
regulators and ultimately to patients, we know
exactly how to make this consistently well. That's
the essence of it. And doing all this, rigorously
adhering to every aspect of CGMP is absolutely
essential for clearing the next major hurdle,
regulatory validation. Okay, so getting the green
light from agencies like the FDA, how does that
work? Well, agencies like the FDA in the US or
the EMA in Europe, they require extensive validation
data before a peptide API can be approved for
use in a drug that's sold to patients. What do
companies have to submit? They submit huge dossiers,
things like new drug applications, NDAs, or for
generics, abbreviated new drug applications,
ANDAs. These contain exhaustive details about
the manufacturing process, all the controls,
all the testing. All that CGMP documentation
we talked about. A huge part of it, yes. Demonstrating
full CGMP compliance is absolutely fundamental
to getting regulatory approval. You have to show
the regulators You're not just saying you follow
good practices, but you have the hard data and
records to back it all up. Proof is required.
Absolutely. And the scrutiny doesn't stop there.
Regulators also require extensive stability studies.
Stability? How long the drug lasts? Exactly.
You need studies based on specific guidelines
to determine the shelf life. How long is the
API stable? How long is the final drug product
stable under specific storage conditions? So
patients know the expiry date is reliable. Precisely.
You need evidence that the product stays within
its quality specifications for its entire intended
shelf life. And those tests have to be reliable
and meaningful. What they call stability indicating
methods. Makes perfect sense. You need confidence
the medicine is still good when you use it. And
one more point here, especially relevant for
generics. If a company wants to make a generic
version of an existing peptide drug. Like a copy
of a brand name one. Essentially yes. They also
have to demonstrate bioequivalence. Bioequivalence,
meaning? Meaning they have to show, usually through
studies in humans, that their generic product
behaves the same way in the body as the original
brand name drug. Gets absorbed at the same rate,
to the same extent. Exactly. No significant difference
in how quickly and how much drug gets into the
bloodstream. It's another significant regulatory
hurdle to ensure that the generic is truly interchangeable
with the innovator product. Wow. So even making
a copy isn't simple. Not at all for complex molecules
like peptides. So, yeah, these key challenges
really stack up. The inherent difficulty of large
-scale peptide synthesis, the absolute necessity
of strict CGMP compliance throughout, and then
the rigorous demands of regulatory validation.
It all underscores just how complex it is to
bring these potentially amazing peptide drugs
to patients. It really is eye -opening. You hear
new drug approved and you don't think about all
that intricate work behind it. Understanding
these steps, it definitely gives you a much deeper
appreciation for the whole journey. Yeah. from
the lab bench discovery to actually having that
medicine available. It's far more than just the
initial science, isn't it? It's this incredible
mix of advanced chemistry, really sophisticated
engineering, super stringent quality control,
and navigating complex regulations. A carefully
orchestrated interplay, absolutely. So thinking
about all this complexity we've discussed, it
does make you wonder, right? As we get better
at finding new peptide therapies, what's next
for making them? That's the big question, isn't
it? What kinds of novel manufacturing technologies
or maybe more innovative regulatory approaches
might come along? Things to help overcome some
of these hurdles, make it maybe faster, cheaper,
or just more efficient. Exactly. How can we streamline
this process to broaden patient access? Because
ultimately, that's the goal, getting these vital
medicines to the people who need them. It's a
field that's constantly evolving. A fascinating
thought to end on. Finding ways to make these
complex processes smoother will be key to unlocking
the full potential